AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Experts said a certain type of bispecific antibody seems to have hit upon a crucial combination of two cancer targets: the proteins VEGF and either PD-1 or PD-L1. “It’s exactly that,” said ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

US-based Aethlon Medical has treated the first subject with its Hemopurifier investigational device in its Australian cancer trial. Designed for subjects with solid tumours, the dose-finding trial ...

In a challenging market environment, NAYA stock has touched a 52-week low, with shares plummeting to $0.35. According to InvestingPro data, the company's financial health score is rated as WEAK, with ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric cancer. Read more here.

Chinese researchers and their collaborators have published data on the bifunctional antibody JS-201, which exerts dual targeting of PD-1 and TGF-β signaling, for the potential treatment of cancer and ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

This Phase 1 study evaluated the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in this challenging p ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is excited to announce that the prestigious medical journal Nature Medicine published the results of the company's independently developed PD-1/CTLA-4 ...